Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other financing activities (2020 - 2024)

Keros Therapeutics (KROS) has disclosed Other financing activities for 4 consecutive years, with $130000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other financing activities rose 381.48% year-over-year to $130000.0, compared with a TTM value of $130000.0 through Dec 2025, down 41.96%, and an annual FY2024 reading of $171000.0, up 81.91% over the prior year.
  • Other financing activities was $130000.0 for Q3 2024 at Keros Therapeutics, up from $67000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $219000.0 in Q1 2020 and bottomed at $8000.0 in Q2 2020.
  • Average Other financing activities over 4 years is $106285.7, with a median of $100000.0 recorded in 2021.
  • The sharpest move saw Other financing activities tumbled 48.19% in 2021, then surged 381.48% in 2024.
  • Year by year, Other financing activities stood at $193000.0 in 2020, then tumbled by 48.19% to $100000.0 in 2021, then tumbled by 33.0% to $67000.0 in 2023, then skyrocketed by 94.03% to $130000.0 in 2024.
  • Business Quant data shows Other financing activities for KROS at $130000.0 in Q3 2024, $67000.0 in Q4 2023, and $27000.0 in Q3 2023.